Dexcom (DXCM) is the largest provider of continuous glucose monitoring system and software. They reported earnings April 28 and missed on EPS but beat on revenue. George Tsilis discusses the miss on EPS and explains Dexcom is aggressively spending on technology and capital expenditures. He compares it to its peers Abbott Labs and Medtronic. Morgan Stanley keeps an outperform rating on Dexcom but lowered its price target to $492 from $514, says George. George explains his bullish short put trade. Tune in for the full discussion.
29 Apr 2022
Trading 360
06 May 2022
Trading 360
24 Feb 2022
Trading 360
23 Feb 2022
Trading 360
09 May 2022
Trading 360
03 May 2022
Trading 360
15 Mar 2022